Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Posts 5-Percent Organic Revenue Growth as Profits Rise 55.5 Percent

NEW YORK, April 28 (GenomeWeb News) - Molecular Devices today said that first-quarter revenue grew 5 percent organically as R&D spending declined 11.3 percent and profits rose 55.5 percent.

 

Total receipts for the three months ended March 31 rose around 2.5 percent to $40 million from $39 million year over year, hurt by foreign currency effects. Without these effects, revenue grew 5 percent, the company said.

 

The company said it "saw excellent growth" in its SpectraMax, FLIPR, and high- content imaging product lines during the quarter. But the firm said this growth was "somewhat offset" by a "weaker than expected" quarter in Europe.

 

"We remain confident, however, that our worldwide life sciences and drug discovery markets will remain stable in the near-term, and we do not expect this weakness to continue," President and CEO Joseph Keegan said in a statement.

 

R&D spending for the period declined to $5.5 million from $6.2 million year over year.

 

First-quarter profits more than doubled to $2.8 million, or $.17 per basic share, from $1.8 million, or $.11 per basic share, year over year.

 

Molecular Devices said it had around $33.2 million in cash and equivalents as of March 31.

 

Looking ahead, the company said it is poised to generate between $49 million and $51 million in second-quarter revenues, or growth of between 10.1 percent and 14.6 percent. Receipts for 2006, meantime, will likely be between $198 million and $206 million, or growth between 9.3 percent and 13.7 percent.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.